Apellis Pharmaceuticals Stock Market Value
| APLS Stock | USD 30.39 0.92 3.12% |
| Symbol | Apellis |
Apellis Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.03) | Revenue Per Share | Quarterly Revenue Growth 0.783 | Return On Assets | Return On Equity |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Apellis Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apellis Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apellis Pharmaceuticals.
| 03/12/2023 |
| 01/30/2025 |
If you would invest 0.00 in Apellis Pharmaceuticals on March 12, 2023 and sell it all today you would earn a total of 0.00 from holding Apellis Pharmaceuticals or generate 0.0% return on investment in Apellis Pharmaceuticals over 690 days. Apellis Pharmaceuticals is related to or competes with Akero Therapeutics, Immunovant, Madrigal Pharmaceuticals, Day One, Amylyx Pharmaceuticals, Terns Pharmaceuticals, and X4 Pharmaceuticals. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and ... More
Apellis Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apellis Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apellis Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.1 | |||
| Information Ratio | 0.032 | |||
| Maximum Drawdown | 27.73 | |||
| Value At Risk | (4.71) | |||
| Potential Upside | 4.63 |
Apellis Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apellis Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apellis Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Apellis Pharmaceuticals historical prices to predict the future Apellis Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0536 | |||
| Jensen Alpha | 0.1391 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.0293 | |||
| Treynor Ratio | 0.2611 |
Apellis Pharmaceuticals Backtested Returns
Apellis Pharmaceuticals appears to be very steady, given 3 months investment horizon. Apellis Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.055, which signifies that the company had a 0.055 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Apellis Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Apellis Pharmaceuticals' mean deviation of 2.51, and Risk Adjusted Performance of 0.0536 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Apellis Pharmaceuticals holds a performance score of 4. The firm shows a Beta (market volatility) of 0.75, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Apellis Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Apellis Pharmaceuticals is expected to be smaller as well. Please check Apellis Pharmaceuticals' maximum drawdown, and the relationship between the information ratio and expected short fall , to make a quick decision on whether Apellis Pharmaceuticals' price patterns will revert.
Auto-correlation | 0.42 |
Average predictability
Apellis Pharmaceuticals has average predictability. Overlapping area represents the amount of predictability between Apellis Pharmaceuticals time series from 12th of March 2023 to 20th of February 2024 and 20th of February 2024 to 30th of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apellis Pharmaceuticals price movement. The serial correlation of 0.42 indicates that just about 42.0% of current Apellis Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 112.58 |
Apellis Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Apellis Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Apellis Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Apellis Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Apellis Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Apellis Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Apellis Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Apellis Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Apellis Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Apellis Pharmaceuticals Lagged Returns
When evaluating Apellis Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Apellis Pharmaceuticals stock have on its future price. Apellis Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Apellis Pharmaceuticals autocorrelation shows the relationship between Apellis Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Apellis Pharmaceuticals.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.